Reaction
Endocrine Disorder reporting signals
As of the last recalculation, Endocrine Disorder appears in 1,261 FAERS reports alongside 22 co-occurring drug terms. The strongest observed disproportionality signal is OLANZAPINE PAMOATE (PRR 57.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Olanzapine Pamoate | 128 | 57.3 | 57.5 |
| Ipilimumab | 95 | 39.2 | 39.3 |
| Atezolizumab | 56 | 24.9 | 24.9 |
| Finasteride | 83 | 24.2 | 24.3 |
| Durvalumab | 29 | 24.1 | 24.1 |
| Olanzapine | 133 | 22.7 | 22.8 |
| Itraconazole | 14 | 20.0 | 20.0 |
| Nivolumab | 107 | 19.9 | 19.9 |
| Cortisone Acetate | 13 | 17.6 | 17.6 |
| Magnesium Hydroxide | 14 | 17.3 | 17.3 |
| Busulfan | 16 | 17.0 | 17.0 |
| Gentamicin | 12 | 15.3 | 15.3 |
| Calcium Gluconate | 11 | 15.2 | 15.2 |
| Gentamicin Sulfate | 12 | 12.6 | 12.7 |
| Dextrose | 9 | 11.4 | 11.4 |
| Pembrolizumab | 68 | 11.2 | 11.2 |
| Dextrose Monohydrate | 9 | 11.2 | 11.2 |
| Thiotepa | 5 | 8.7 | 8.7 |
| Deferasirox | 13 | 8.2 | 8.2 |
| Panitumumab | 6 | 6.3 | 6.3 |
| Somatropin | 27 | 6.2 | 6.2 |
| Carfilzomib | 8 | 4.7 | 4.7 |